EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells

Antonio Carusillo, Sibtain Haider, Raul Schäfer, Manuel Rhiel, Daniel Türk, Kay O Chmielewski, Julia Klermund, Laura Mosti, Geoffroy Andrieux, Richard Schäfer, Tatjana I Cornu, Toni Cathomen und 1 weitere

Nucleic Acids Research · 22.05.2023 · 51 (9) · 4660-4673

DOI: 10.1093/nar/gkad255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 18.04.2023. Verfasst von Antonio Carusillo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg 79106, Germany. Hauptthemen laut MEDLINE: CRISPR-Associated Protein 9, Gene Editing. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union's Horizon 2020, German Research Foundation, Medical Informatics Funding Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precise genome editing requires the resolution of nuclease-induced DNA double strand breaks (DSBs) via the homology-directed repair (HDR) pathway. In mammals, this is typically outcompeted by non-homologous end-joining (NHEJ) that can generate potentially genotoxic insertion/deletion mutations at DSB sites. Because of higher efficacy, clinical genome editing has been restricted to imperfect but efficient NHEJ-based approaches. Hence, strategies that promote DSB resolution via HDR are essential to facilitate clinical transition of HDR-based editing strategies and increase safety. Here we describe a novel platform that consists of a Cas9 fused to DNA repair factors to synergistically inhibit NHEJ and favor HDR for precise repairing of Cas-induced DSBs. Compared to canonical CRISPR/Cas9, the increase in error-free editing ranges from 1.5-fold to 7-fold in multiple cell lines and in primary human cells. This novel CRISPR/Cas9 platform accepts clinically relevant repair templates, such as oligodeoxynucleotides (ODNs) and adeno-associated virus (AAV)-based vectors, and has a lower propensity to induce chromosomal translocations as compared to benchmark CRISPR/Cas9. The observed reduced mutational burden, resulting from diminished indel formation at on- and off-target sites, provides a remarkable gain in safety and advocates this novel CRISPR system as an attractive tool for therapeutic applications depending on precision genome editing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Associated Protein 9Gene EditingHumansCRISPR-Cas SystemsDNA Breaks, Double-StrandedDNA End-Joining RepairDNA RepairRecombinational DNA Repair

Substanzen

CRISPR-Associated Protein 9

Autor:innen und Institutionen

  • Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg 79106, Germany.
  • Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Freiburg 79106, Germany.
  • Ph.D. Program, Faculty of Biology, University of Freiburg, Freiburg 79106, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Freiburg 79106, Germany.
  • Faculty of Medicine, University of Freiburg, 79106, Germany.
  • Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe University Hospital, Frankfurt am Main, 60596, Germany.

ORCID-Profile: Claudio Mussolino

Förderung

  • European Union's Horizon 2020
  • German Research Foundation
  • Medical Informatics Funding Scheme
  • University of Freiburg

Zitieren

APA

Carusillo, A., Haider, S., Schäfer, R., Rhiel, M., Türk, D., Chmielewski, K. O., Klermund, J., Mosti, L., Andrieux, G., Schäfer, R., Cornu, T. I., Cathomen, T., & Mussolino, C. (2023). A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells. Nucleic Acids Research, 51(9), 4660-4673. https://doi.org/10.1093/nar/gkad255

Vancouver

Carusillo A, Haider S, Schäfer R, Rhiel M, Türk D, Chmielewski KO, et al. A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells. Nucleic Acids Research. 2023;51(9):4660-4673. doi:10.1093/nar/gkad255

BibTeX
@article{Carusillo2023,
  author = {Carusillo, Antonio and Haider, Sibtain and Schäfer, Raul and Rhiel, Manuel and Türk, Daniel and Chmielewski, Kay O and Klermund, Julia and Mosti, Laura and Andrieux, Geoffroy and Schäfer, Richard and Cornu, Tatjana I and Cathomen, Toni and Mussolino, Claudio},
  title = {A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells},
  journal = {Nucleic Acids Research},
  year = {2023},
  volume = {51},
  number = {9},
  pages = {4660--4673},
  doi = {10.1093/nar/gkad255}
}
Kostenlos starten →